ArticleEarly intervention in psychiatry2025
Long-Acting Injectable Antipsychotic Use and Discontinuation Rates in Children and Adolescents With Schizophrenia Using Medicaid Claims Data.
Article in Early intervention in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Acting Injectable Antipsychotic Use and Discontinuation Rates in Children and Adolescents With Schizophrenia Using Medicaid Claims Data.Early intervention in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe primary objective was to analyse the prescribing and discontinuation rates of long-acting injectable (LAI) antipsychotics among child and adolescent populations. The secondary objective was to assess if racial/ethnic differences existed between LAI antipsychotics and discontinuation rates.
methodsChildren and adolescents (2-17 years old) with schizophrenia or related disorders who received LAI antipsychotics between January 1, 2017 and December 31, 2021 were identified using Merative MarketScan Multi-State Medicaid Database. Descriptive statistics summarised the rates of LAI antipsychotic use. Kaplan-Meier survival curves were examined, and Cox regression analyses conducted to compare the hazard of discontinuation across LAI antipsychotics (p < 0.05).
resultsA total of 1277 out of 67 502 patients were included in the final analysis. The average age was 15.4 ± 1.7 years (range 7-17 years). Approximately 59% were male, with the most common races identified being Black (48%) and White (38%). Prescribing of LAI second-generation antipsychotics occurred in about 94% of the population. The most common LAI antipsychotics prescribed included paliperidone palmitate 1 month (40%) and aripiprazole formulations (48%). When controlling for age group, gender and plan type, the discontinuation rate for paliperidone and aripiprazole formulations did not differ. However, LAI paliperidone palmitate was associated with a 46% lower hazard of discontinuation for White compared to Black populations (HR = 0.54; p = 0.01).
conclusionDespite the limited sample, this study explored the frequency of prescribing and discontinuation rates between LAI antipsychotics in children. Future studies may further explain the unique challenges (e.g., reasons for discontinuation) and economic impact LAI antipsychotics present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.